A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy

This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.

Inclusion Criteria:

• adult patients >=18 years of age;
• advanced or metastatic liver cancer;
• >=1 measurable lesion.

Exclusion Criteria:

• current radiotherapy, chemotherapy, or other experimental therapies;
• prior cytotoxic chemotherapy;
• major surgery, open biopsy, or traumatic injury within 28 days of study entry;
• history of a malignancy during the last 5 years, other than cutaneous basal cell cancer or in situ cervical cancer.